CCR5 and HIV-1 infection: A HIV-1 entry inhibitor, maraviroc (also known as Selzentry or MVC) that is clinically approved by the U.S. Food and Drug Administration (FDA) is a CCR5-targeting small molecule shown to reduce HIV-1 infection in patients.